Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1279 - Hypomagnesaemia in the context of cetuximab/panitumumab and proton pump inhibitor therapy


17 Dec 2016


Poster lunch


Rohit Joshi


Annals of Oncology (2016) 27 (suppl_9): ix1-ix8. 10.1093/annonc/mdw573


P. Connolly1, T. Foo1, J. Rowe1, R. Joshi2

Author affiliations

  • 1 Medical Oncology, Lyell McEwin Hospital, 5112 - Adelaide/AU
  • 2 Medical Oncology, Elizabeth Vale, Lyell McEwin Hospital, 5112 - Adelaide/AU


Abstract 1279


The epidermal growth factor inhibitors cetuximab and panitumumab are associated with hypomagnesaemia. Proton pump inhibitors (PPIs) also have a similar association. The aim of our study was to determine whether patients on both classes of agents develop more significant levels of hypomagnesaemia; which might have potential therapeutic implications.


This study was performed as a retrospective cohort analysis. Fifty consecutive patients treated with cetuximab or panitumumab were selected from our oncology database. Their medical records were reviewed to determine: if they were receiving PPI therapy or other agents contributing to hypomagnesaemia, if they received magnesium supplementation, and the presence of depressive illness. Magnesium levels before, during and after treatment were recorded. Linear mixed-effects models and logistic generalised estimating equation (GEE) models were used for statistical analysis. Unstructured covariance structure was used within the linear mixed-effects model as it resulted in the model of best-fit.


Cetuximab and panitumumab were associated with significant reductions in serum magnesium levels (p 


EGFR inhibitor therapy is associated with hypomagnesaemia. There was a correlation between depression and low magnesium levels. Further investigation is warranted to evaluate the links between these medical conditions, and the role of PPI therapy and magnesium supplementation.

Clinical trial indentification


Legal entity responsible for the study

South Australia Department of Health




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings